The FDA has approved the first drug against the mortal type of breast cancer. Lynparza, unlike its predecessors, treats HER2/neu negative cancer, which has been increasing in the last years, giving hope to patients suffering from this terrible disease.
Biogen’s big seller drug Adulhem has been retired from Medicare and Medicaid after failing to prove a real benefit to the patients suffering from Alzheimer’s disease. Is this going to affect the market value of Biogen? What is next in the Alzheimer’s medication?